The profile humoral immunoreactivity in survivors of ebolavirus Sudan

E is a member of the family Filoviridae and the cause of Ebola hemorrhagic fever (EHF). Since it was first recognized in 1976, more than 18 outbreaks have occurred involving more than 2000 human cases, 1400 deaths, and with a case fatality rate that ranged from 30-90%. During the last decade, much research focused on the human immune response to ebolavirus to investigate the role of humoral immunity to different viral epitopes. Although there have been great efforts in this regard, the profile of specific humoral immunoreactivity to viral proteins during viral infection and their role in immunity and/or recovery from disease is still poorly understood. As such, we performed a study to characterize the human humoral immune response to the individual viral proteins of ebolavirus Sudan (strain Gulu). Our studies compared the profile of humoral immunoreactivity in serum of survivors versus non survivors of ebolavirus infection, to identify patterns of specific viral protein and epitope recognition that might correlate with a positive disease outcome. The results of our work thus far have supported previous published data and contributed to further understanding the humoral immune response, and its recognition profile to specific viral targets, following ebolavirus infection in human survivors.